Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia

S. Toma, P. E. Mangiante, G. Margarino, G. Nicolo, R. Palumbo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

16 patients with oral leukoplakia were treated with oral 13-cis-retinoic acid. The initial dose, given for 3 months, was 0.2 mg/kg/day, increasing by a further 0.2 mg/kg/day in successive 3 month cycles. The maximum dosage reached at 1.0 mg/kg/day, was given to only 2 patients (who received a total of 15 months treatment). However, 10 patients completed the cycle at 0.8 mg/kg/day (12 months treatment in total), but treatment could not continue due to toxicity (grade I and II), which was cutaneous, mucosal, and haematological (hypertriglyceridemia and hypercholesterolemia). There was grade III toxicity in the skin and mucosa in only 1 case, a patient treated at a dose of 1.0 mg/kg/day. The toxicity was reversible in all cases. 14 of the patients completed the trial. In 4 there were improvements graded as partial responses (PR) obtained at 0.2 mg/kg/day (3PR) and 0.6 (1PR) and there was one complete response (CR) obtained at 0.4 mg/kg/day. Overall there was thus an objective response rate of 36% who showed 50% or more reduction in lesion size. After the retinoic acid treatment was stopped, patients were followed-up for 12 months; 2 patients showed regression of the responses obtained after 6 and 9 months. This study shows that oral treatment with 13-cis-retinoic acid at low dosages is efficacious and with minimal toxicity. It also shows that it is not feasible to treat these patients at doses above 0.8 mg/kg/day for long periods-mainly due to poor compliance.

Original languageEnglish
Pages (from-to)121-123
Number of pages3
JournalEuropean Journal of Cancer. Part B: Oral Oncology
Volume28
Issue number2
DOIs
Publication statusPublished - 1992

Fingerprint

Oral Leukoplakia
Isotretinoin
Therapeutics
Skin
Hypertriglyceridemia
Tretinoin
Hypercholesterolemia
Mucous Membrane

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia. / Toma, S.; Mangiante, P. E.; Margarino, G.; Nicolo, G.; Palumbo, R.

In: European Journal of Cancer. Part B: Oral Oncology, Vol. 28, No. 2, 1992, p. 121-123.

Research output: Contribution to journalArticle

Toma, S. ; Mangiante, P. E. ; Margarino, G. ; Nicolo, G. ; Palumbo, R. / Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia. In: European Journal of Cancer. Part B: Oral Oncology. 1992 ; Vol. 28, No. 2. pp. 121-123.
@article{6db7e30ccf8d46c98bcf13655eda3572,
title = "Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia",
abstract = "16 patients with oral leukoplakia were treated with oral 13-cis-retinoic acid. The initial dose, given for 3 months, was 0.2 mg/kg/day, increasing by a further 0.2 mg/kg/day in successive 3 month cycles. The maximum dosage reached at 1.0 mg/kg/day, was given to only 2 patients (who received a total of 15 months treatment). However, 10 patients completed the cycle at 0.8 mg/kg/day (12 months treatment in total), but treatment could not continue due to toxicity (grade I and II), which was cutaneous, mucosal, and haematological (hypertriglyceridemia and hypercholesterolemia). There was grade III toxicity in the skin and mucosa in only 1 case, a patient treated at a dose of 1.0 mg/kg/day. The toxicity was reversible in all cases. 14 of the patients completed the trial. In 4 there were improvements graded as partial responses (PR) obtained at 0.2 mg/kg/day (3PR) and 0.6 (1PR) and there was one complete response (CR) obtained at 0.4 mg/kg/day. Overall there was thus an objective response rate of 36{\%} who showed 50{\%} or more reduction in lesion size. After the retinoic acid treatment was stopped, patients were followed-up for 12 months; 2 patients showed regression of the responses obtained after 6 and 9 months. This study shows that oral treatment with 13-cis-retinoic acid at low dosages is efficacious and with minimal toxicity. It also shows that it is not feasible to treat these patients at doses above 0.8 mg/kg/day for long periods-mainly due to poor compliance.",
author = "S. Toma and Mangiante, {P. E.} and G. Margarino and G. Nicolo and R. Palumbo",
year = "1992",
doi = "10.1016/0964-1955(92)90039-4",
language = "English",
volume = "28",
pages = "121--123",
journal = "European Journal of Cancer Part B: Oral Oncology",
issn = "0964-1955",
publisher = "Pergamon Press Ltd.",
number = "2",

}

TY - JOUR

T1 - Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia

AU - Toma, S.

AU - Mangiante, P. E.

AU - Margarino, G.

AU - Nicolo, G.

AU - Palumbo, R.

PY - 1992

Y1 - 1992

N2 - 16 patients with oral leukoplakia were treated with oral 13-cis-retinoic acid. The initial dose, given for 3 months, was 0.2 mg/kg/day, increasing by a further 0.2 mg/kg/day in successive 3 month cycles. The maximum dosage reached at 1.0 mg/kg/day, was given to only 2 patients (who received a total of 15 months treatment). However, 10 patients completed the cycle at 0.8 mg/kg/day (12 months treatment in total), but treatment could not continue due to toxicity (grade I and II), which was cutaneous, mucosal, and haematological (hypertriglyceridemia and hypercholesterolemia). There was grade III toxicity in the skin and mucosa in only 1 case, a patient treated at a dose of 1.0 mg/kg/day. The toxicity was reversible in all cases. 14 of the patients completed the trial. In 4 there were improvements graded as partial responses (PR) obtained at 0.2 mg/kg/day (3PR) and 0.6 (1PR) and there was one complete response (CR) obtained at 0.4 mg/kg/day. Overall there was thus an objective response rate of 36% who showed 50% or more reduction in lesion size. After the retinoic acid treatment was stopped, patients were followed-up for 12 months; 2 patients showed regression of the responses obtained after 6 and 9 months. This study shows that oral treatment with 13-cis-retinoic acid at low dosages is efficacious and with minimal toxicity. It also shows that it is not feasible to treat these patients at doses above 0.8 mg/kg/day for long periods-mainly due to poor compliance.

AB - 16 patients with oral leukoplakia were treated with oral 13-cis-retinoic acid. The initial dose, given for 3 months, was 0.2 mg/kg/day, increasing by a further 0.2 mg/kg/day in successive 3 month cycles. The maximum dosage reached at 1.0 mg/kg/day, was given to only 2 patients (who received a total of 15 months treatment). However, 10 patients completed the cycle at 0.8 mg/kg/day (12 months treatment in total), but treatment could not continue due to toxicity (grade I and II), which was cutaneous, mucosal, and haematological (hypertriglyceridemia and hypercholesterolemia). There was grade III toxicity in the skin and mucosa in only 1 case, a patient treated at a dose of 1.0 mg/kg/day. The toxicity was reversible in all cases. 14 of the patients completed the trial. In 4 there were improvements graded as partial responses (PR) obtained at 0.2 mg/kg/day (3PR) and 0.6 (1PR) and there was one complete response (CR) obtained at 0.4 mg/kg/day. Overall there was thus an objective response rate of 36% who showed 50% or more reduction in lesion size. After the retinoic acid treatment was stopped, patients were followed-up for 12 months; 2 patients showed regression of the responses obtained after 6 and 9 months. This study shows that oral treatment with 13-cis-retinoic acid at low dosages is efficacious and with minimal toxicity. It also shows that it is not feasible to treat these patients at doses above 0.8 mg/kg/day for long periods-mainly due to poor compliance.

UR - http://www.scopus.com/inward/record.url?scp=0026464954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026464954&partnerID=8YFLogxK

U2 - 10.1016/0964-1955(92)90039-4

DO - 10.1016/0964-1955(92)90039-4

M3 - Article

VL - 28

SP - 121

EP - 123

JO - European Journal of Cancer Part B: Oral Oncology

JF - European Journal of Cancer Part B: Oral Oncology

SN - 0964-1955

IS - 2

ER -